Claim OwnershipOptimum Perspectives
Subscribed: 1Played: 6
Subscribe
© Optimum Strategic Communications
Description
Follow us on Linkedin and Twitter for news and highlights on the life sciences industry. Reach out via our contact page on our website: www.optimumcomms.com
Hosted on Acast. See acast.com/privacy for more information.
27 Episodes
Reverse
In this podcast to mark Lung Cancer Awareness Month, Optimum’s Richard Staines speaks to Roman Thomas, CEO and founder of Disco Pharmaceuticals, on breakthroughs that have improved patient outcomes, and the company’s efforts to help develop new therapies with its “surfaceome” technology. Hosted on Acast. See acast.com/privacy for more information.
Optimum’s Richard Staines talks to Feride Sahin, Senior Director of Clinical Development at Splice Bio about the importance of World Sight Day, which takes place this week. Hosted on Acast. See acast.com/privacy for more information.
It’s time to talk about mushrooms! Or rather the deadly toxin amanitin found in the death cap mushroom, which Heidelberg Pharma is using as a cancer drug with the help of a tumour-targeting antibody, find out more in this episode featuring Heidelberg Pharma's CEO, Andreas Pahl. Hosted on Acast. See acast.com/privacy for more information.
Check out Optimum’s latest podcast episode profiling our client Resolution Therapeutics. Lara Campana, VP of Research Operations outlines the company’s technology based around pro-regenerative macrophages and its potential to treat liver disease. Hosted on Acast. See acast.com/privacy for more information.
Dr Ruth McKernan CBE is the richly deserved winner of the 2024 Mediscience Award for ‘Most Significant Contribution to the Mediscience Sector’. In this episode Optimum’s Eva Haas discusses the highlights of Ruth’s incredible career, the skills needed for success as a company founder and the heartening advancements in treating neurodegenerative diseases such as Alzheimer's in recent years. Hosted on Acast. See acast.com/privacy for more information.
Listen to expert discussion on the role of AI in drug development, featuring Tushar Pandey, CEO and Co-founder of SimBioSys, and Jeremy Skillington, CEO of Poolbeg Pharma. Hosted on Acast. See acast.com/privacy for more information.
Southampton-based Curve Therapeutics recently raised a hefty £40m in a Series A financing round. In this in-depth podcast, CEO Simon Kerry describes how investors fell in love with Curve’s “Microcycle” based discovery platform, which gives the company “the ability to potentially identify drugs against very difficult, challenging targets”.He explains how Curve’s platform enables them to spot drugs with a higher chance of working in real-world conditions. He also outlines the firm’s lead programme – which aims to block two cancer targets called Hypoxia Inducible Factors, or “HIFs”, which enable solid tumours to survive in low-oxygen conditions.Speaking to Optimum’s Stephen Adams, Simon ponders the role of luck in securing investment, both “the kind you deserve because you turn over a lot of stones”, and the more fortuitous variety. Hosted on Acast. See acast.com/privacy for more information.
Listen to the latest insights from Gil Bar-Nahum, Managing Director in the Global Healthcare Investment Banking Group, Jefferies International, on how to succeed in the new wave of biotech IPOs in the Optimum Perspectives podcast. Hosted on Acast. See acast.com/privacy for more information.
Check out Optimum’s latest Optimum Perspectives Podcast episode featuring the stars of the 20th Anglonordic Life Science Conference in London. Hear industry leaders give their thoughts on trends within the life science industry and the optimistic mood of the markets in 2024! Hosted on Acast. See acast.com/privacy for more information.
Diverse recruitment for clinical trials is a huge issue – but what can drug developers do to overcome this challenge? Join Optimum’s Richard Staines as he discuses this thorny issue with Ariceum Therapeutic’s CMO, Germo Gericke, Leucid Bio’s CSO, John Maher and Non-Executive Director & Thought Leader Annalisa Jenkins. Hosted on Acast. See acast.com/privacy for more information.
Following recent encouraging interim clinical results, hear Øystein Rekdal, CEO of Lytix Biopharma, discuss with Optimum's Nick Bastin how the company's lead candidate LTX-315 has a unique approach to killing cancer. Hosted on Acast. See acast.com/privacy for more information.
To mark Rare Disease Day on 29 February, Optimum Perspectives podcast interviews a panel of experts who discuss the opportunities and challenges for developers of therapies for rare diseases in 2024. Hosted on Acast. See acast.com/privacy for more information.
In this Optimum Perspectives celebratory episode for International Day of Women & Girls in Science, hear from five influential women on how they broke down gender barriers to succeed in the life science industry. Chaired by esteemed journalist Lisa Urquhart, hear guest speakers Renee Aguiar-Lucander of Calliditas, Lene Gerlach of EIR Ventures & WiLD, Bita Sehat of Trill Impact, and Ninna Struck Rossen of Metsystem, share their stories on being women in life sciences, and how to succeed in the industry. Hosted on Acast. See acast.com/privacy for more information.
Happy 1st birthday to the Optimum Perspectives Podcast! Since launching, 1000s of listens have grown the show into an excellent hub of intel from top tier life science guests. Listen now to our anniversary special, where Optimum's Mary Clark, Nick Bastin and Eva Haas discuss the findings of our insightful European Life Sciences Investor survey! Hosted on Acast. See acast.com/privacy for more information.
Hear Vicore Pharma’s CEO, Ahmed Mousa speak to Optimum's Richard Staines on their new treatment for Idiopathic Pulmonary Fibrosis (IPF), C21. It aims to improve available treatments for patients of IPF by halting the progression of fibrosis and has the aim of restoring lung function. Hosted on Acast. See acast.com/privacy for more information.
In this insightful and emotional podcast episode, the co-founder of Ariana Smiles - a Special Named Fund at CCLG UK, Stephanie Seales Gabbitas shares her mission to improve the lives of children diagnosed with Leukaemia by raising funds for research into precision oncology medicine. Hosted on Acast. See acast.com/privacy for more information.
There is a lack of effective treatments for Cutaneous T-Cell Lymphoma (CTCL) – in this podcast episode Jason Loveridge, CEO of 4SC, talked to Optimum Strategic Communications’ Eva Haas about the Company’s potential new maintenance therapy Kinselby (resminostat). 4SC is a late-stage biotech improving lives for patients suffering with advanced-stage Cutaneous T Cell Lymphoma (CTCL).It has developed Kinselby (resminostat), a novel, oral, maintenance treatment targeting advanced-CTCL, a rare type of non-Hodgkin lymphoma that affects the skin. There are no drugs in development or on the market as maintenance therapy for CTCL.Kinselby (resminostat) is an orally administered histone deacetylase (HDAC) inhibitor that has produced supportive results in the pivotal RESMAIN trial, where it postponed disease progression in patients – a new treatment paradigm in CTCL. Hosted on Acast. See acast.com/privacy for more information.
Optimum celebrated its 15th Annual Healthcare Investor Conference – marking its crystal anniversary – and what a sparkler it was! In the latest episode of Optimum Perspectives Podcast, Richard Staines talks through the top takeaways from the October event with special testimonials from our guests. Hosted on Acast. See acast.com/privacy for more information.
Episode 9 of Optimum Perspectives Podcast features Optimum's Richard Staines and Eva Haas, who discuss the hot areas for investment in the shifting biotech market – including antibody-drug conjugates, smart radiotherapies, mRNA and immune-oncology. Want us to explore a topic further? Let us know! Hosted on Acast. See acast.com/privacy for more information.
Alchemab aims to revolutionise drug discovery with a novel alternative to the classic “choose a target” approach. Alchemab specifically looks to identify shared antibodies from people who have shown resilience to disease – the unexpectedly well. The company then uses its proprietary technology to identify which targets these antibodies are binding to, and what diseases these targets are associated with. Optimum Strategic Communications’ Richard Staines caught up with Alchemab’s CEO, Young Kwon, to find out more. Hosted on Acast. See acast.com/privacy for more information.
Comments
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
Download from Google Play
Download from App Store
United States